Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age
- PMID: 37463688
- PMCID: PMC10353914
- DOI: 10.3346/jkms.2023.38.e217
Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has caused the death of thousands of patients worldwide. Although age is known to be a risk factor for morbidity and mortality in COVID-19 patients, critical illness or death is occurring even in the younger age group as the epidemic spreads. In early 2022, omicron became the dominant variant of the COVID-19 virus in South Korea, and the epidemic proceeded on a large scale. Accordingly, this study aimed to determine whether young adults (aged ≤ 50 years) with critical COVID-19 infection during the omicron period had different characteristics from older patients and to determine the risk factors for mortality in this specific age group.
Methods: We evaluated 213 critical adult patients (high flow nasal cannula or higher respiratory support) hospitalized for polymerase chain reaction-confirmed COVID-19 in nine hospitals in South Korea between February 1, 2022 and April 30, 2022. Demographic characteristics, including body mass index (BMI) and vaccination status; underlying diseases; clinical features and laboratory findings; clinical course; treatment received; and outcomes were collected from electronic medical records (EMRs) and analyzed according to age and mortality.
Results: Overall, 71 critically ill patients aged ≤ 50 years were enrolled, and 142 critically ill patients aged over 50 years were selected through 1:2 matching based on the date of diagnosis. The most frequent underlying diseases among those aged ≤ 50 years were diabetes and hypertension, and all 14 patients who died had either a BMI ≥ 25 kg/m² or an underlying disease. The total case fatality rate among severe patients (S-CFR) was 31.0%, and the S-CFR differed according to age and was higher than that during the delta period. The S-CFR was 19.7% for those aged ≤ 50 years, 36.6% for those aged > 50 years, and 38.1% for those aged ≥ 65 years. In multivariate analysis, age (odds ratio [OR], 1.084; 95% confidence interval [CI], 1.043-1.127), initial low-density lipoprotein > 600 IU/L (OR, 4.782; 95% CI, 1.584-14.434), initial C-reactive protein > 8 mg/dL (OR, 2.940; 95% CI, 1.042-8.293), highest aspartate aminotransferase > 200 IU/L (OR, 12.931; 95% CI, 1.691-98.908), and mechanical ventilation implementation (OR, 3.671; 95% CI, 1.294-10.420) were significant independent predictors of mortality in critical COVID-19 patients during the omicron wave. A similar pattern was shown when analyzing the data by age group, but most had no statistical significance owing to the small number of deaths in the young critical group. Although the vaccination completion rate of all the patients (31.0%) was higher than that in the delta wave period (13.6%), it was still lower than that of the general population. Further, only 15 (21.1%) critically ill patients aged ≤ 50 years were fully vaccinated. Overall, the severity of hospitalized critical patients was significantly higher than that in the delta period, indicating that it was difficult to find common risk factors in the two periods only with a simple comparison.
Conclusion: Overall, the S-CFR of critically ill COVID-19 patients in the omicron period was higher than that in the delta period, especially in those aged ≤ 50 years. All of the patients who died had an underlying disease or obesity. In the same population, the vaccination rate was very low compared to that in the delta wave, indicating that non-vaccination significantly affected the progression to critical illness. Notably, there was a lack of prescription for Paxlovid for these patients although they satisfied the prescription criteria. Early diagnosis and active initial treatment was necessary, along with the proven methods of vaccination and personal hygiene. Further studies are needed to determine how each variant affects critically ill patients.
Keywords: COVID-19; Critical; Mortality; Omicron Variant; Risk Factors; Young.
© 2023 The Korean Academy of Medical Sciences.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures
Similar articles
-
Clinical Characteristics and Risk Factors for Mortality in Critical Coronavirus Disease 2019 Patients 50 Years of Age or Younger During the Delta Wave: Comparison With Patients > 50 Years in Korea.J Korean Med Sci. 2022 Jun 6;37(22):e175. doi: 10.3346/jkms.2022.37.e175. J Korean Med Sci. 2022. PMID: 35668685 Free PMC article.
-
Clinical Characteristics and Outcomes of Children With SARS-CoV-2 Infection During the Delta and Omicron Variant-Dominant Periods in Korea.J Korean Med Sci. 2023 Mar 6;38(9):e65. doi: 10.3346/jkms.2023.38.e65. J Korean Med Sci. 2023. PMID: 36880106 Free PMC article.
-
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35143466 Free PMC article.
-
[Effect of the Omicron variant on cumulative incidence of infection and lethality during the sixth wave of the COVID-19 epidemic in Spain].Semergen. 2024 Mar;50(2):102073. doi: 10.1016/j.semerg.2023.102073. Epub 2023 Oct 13. Semergen. 2024. PMID: 37839336 Review. Spanish.
-
Reparixin improves survival in critically ill and transplant patients: A meta-analysis.Eur J Clin Invest. 2023 Oct;53(10):e14015. doi: 10.1111/eci.14015. Epub 2023 May 9. Eur J Clin Invest. 2023. PMID: 37161521 Review.
Cited by
-
Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service.PLoS One. 2024 Mar 14;19(3):e0300306. doi: 10.1371/journal.pone.0300306. eCollection 2024. PLoS One. 2024. PMID: 38483919 Free PMC article.
-
Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.J Korean Med Sci. 2023 Nov 27;38(46):e396. doi: 10.3346/jkms.2023.38.e396. J Korean Med Sci. 2023. PMID: 38013649 Free PMC article.
-
Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.BMC Infect Dis. 2024 Sep 3;24(1):871. doi: 10.1186/s12879-024-09765-4. BMC Infect Dis. 2024. PMID: 39223456 Free PMC article.
References
-
- World Health Organization. Weekly Epidemiological Update on COVID-19 - 24 August 2022. Geneva, Switzerland: World Health Organization; 2022.
-
- Korea Disease Control and Prevention Agency. Variants of COVID-19. [Updated 2021]. [Accessed August 30, 2022]. https://ncv.kdca.go.kr/hcp/page.do?mid=060102 .
-
- Korea Disease Control and Prevention Agency. Analysis of the COVID-19 Outbreak During the Category 1 Statutory Infectious Disease Designation Period. Cheongju, Korea: Korea Disease Control and Prevention Agency; 2022.
-
- Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 omicron variant. N Engl J Med. 2022;386(7):e14. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous